The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation
- PMID: 33039969
- DOI: 10.1016/j.intimp.2020.107059
The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation
Abstract
Kidney transplantation is the target method of treating chronic kidney disorders. It improves the comfort of patient life by eliminating the need for repeated dialysis. The aim of the study was to examine the correlation between tacrolimus (TAC) dose and genetic variation for interleukin-10 (IL-10) and its effect on the therapeutic outcome. In addition, the correlations between the IL-10 polymorphism andthe clinical and the biochemical parameters of TAC patients were also analyzed. The study included 209 subjects after kidney transplantation, who received TAC every 12 and 24 h. Drug concentrations in blood, selected morphological and biochemical parameters, and the genetic variation of IL-10 (-1082A > G) which may affect immunosuppressant dosage and risk of acute graft rejection were analyzed. Genetic analyses were performed using real-time PCR. No significant correlations between the clinical and the biochemical parameters and IL-10-1082A > G polymorphism for patients receiving TAC after kidney transplantation were found. The analysis of the correlation between TAC dose and IL-10 genetic variation for the -1082A > G polymorphism revealed that patients with the AA genotype required lower immunosuppressive drug doses (AA: 3.54 ± 2.38 mg/day vs AG: 6.18 ± 5.10 mg/day, GG: 4.44 ± 3.01 mg/day). Furthermore, frequencies of the genotypes for the IL-10 -1082A > G polymorphism were characterized by a significantly higher frequency of the AA genotype among TAC 24 as compared to TAC 12 patients. The results of the study indicated that the IL-10 -1082A > G polymorphism may in fact influence the TAC dose. The biochemical parameters of the renal profile in relation to the IL-10 genetic variations were not indicative of higher risk of acute rejection after transplantation.
Keywords: Immunosuppressive drugs; Interleukin-10; Personalized therapy; Polymorphism; Renal transplantation; Tacrolimus.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis.Pharmacogenomics. 2024;25(7):315-327. doi: 10.1080/14622416.2024.2379227. Epub 2024 Jul 29. Pharmacogenomics. 2024. PMID: 39069949 Free PMC article.
-
Pharmacogenetic analysis of interleukin-10 variants and tacrolimus metabolism in kidney transplant patients from Pakistani population.Mol Biol Rep. 2024 Aug 31;51(1):947. doi: 10.1007/s11033-024-09873-z. Mol Biol Rep. 2024. PMID: 39215891
-
Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.Sci Rep. 2021 Sep 2;11(1):17531. doi: 10.1038/s41598-021-96457-7. Sci Rep. 2021. PMID: 34475433 Free PMC article.
-
Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.Drugs. 2019 Dec;79(18):1947-1962. doi: 10.1007/s40265-019-01217-7. Drugs. 2019. PMID: 31713065 Free PMC article.
-
Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1225-1236. doi: 10.1080/17425255.2017.1395413. Epub 2017 Oct 30. Expert Opin Drug Metab Toxicol. 2017. PMID: 29084469 Review.
Cited by
-
Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis.Pharmacogenomics. 2024;25(7):315-327. doi: 10.1080/14622416.2024.2379227. Epub 2024 Jul 29. Pharmacogenomics. 2024. PMID: 39069949 Free PMC article.
-
A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients.Pharmaceutics. 2023 Nov 3;15(11):2580. doi: 10.3390/pharmaceutics15112580. Pharmaceutics. 2023. PMID: 38004558 Free PMC article.
-
Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases.Int J Mol Sci. 2022 Jan 7;23(2):647. doi: 10.3390/ijms23020647. Int J Mol Sci. 2022. PMID: 35054831 Free PMC article. Review.
-
Pharmacogenetic analysis of interleukin-10 variants and tacrolimus metabolism in kidney transplant patients from Pakistani population.Mol Biol Rep. 2024 Aug 31;51(1):947. doi: 10.1007/s11033-024-09873-z. Mol Biol Rep. 2024. PMID: 39215891
-
Xuebijing Protects Against Septic Acute Liver Injury Based on Regulation of GSK-3β Pathway.Front Pharmacol. 2021 Apr 30;12:627716. doi: 10.3389/fphar.2021.627716. eCollection 2021. Front Pharmacol. 2021. PMID: 33995024 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical